[
  {
    "patient_id": "PATIENT_32EFBAC6",
    "drug": "Codeine",
    "timestamp": "2026-02-19T16:51:46.690575",
    "risk_assessment": {
      "risk_label": "Adjust Dosage",
      "confidence_score": 0.95,
      "severity": "moderate"
    },
    "cpic_guidelines": {
      "recommendation_level": "2A",
      "strength_of_recommendation": "Moderate",
      "clinical_guidance": "Reduced metabolism leads to lower morphine conversion (10-20% reduction).",
      "cpic_evidence": "2A - Moderate",
      "reference": "PharmGKB CPIC Codeine/CYP2D6"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "CYP2D6",
      "diplotype": "*1/*2",
      "phenotype": "IM",
      "detected_variants": [
        {
          "rsid": "rs3288976",
          "gene": "CYP2D6",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "CYP2C19",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "CYP2C9",
          "genotype": "*1/*2",
          "phenotype": "Normal Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "TPMT",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs7364978",
          "gene": "SLC01B1",
          "genotype": "*2/*2",
          "phenotype": "Unknown"
        },
        {
          "rsid": "rs3288976",
          "gene": "DPYD",
          "genotype": "*1/*2",
          "phenotype": "Normal Metabolizer"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Consider higher than normal dose or shorter dosing intervals; monitor pain response",
      "dosing": "120-150% of standard dose may be needed% adjustment",
      "monitoring": "Assess pain control; titrate dose based on response (may need 30-60 mg per dose)"
    },
    "llm_generated_explanation": {
      "summary": "Based on genetic profile, Codeine shows adjust dosage risk.",
      "clinical_impact": "CYP2D6 (Intermediate Metabolizer): Adjust Dosage"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": [
        "CYP2D6",
        "CYP2C19",
        "CYP2C9",
        "TPMT",
        "SLC01B1",
        "DPYD"
      ],
      "variant_count": 6,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v2"
    }
  },
  {
    "patient_id": "PATIENT_32EFBAC6",
    "drug": "Warfarin",
    "timestamp": "2026-02-19T16:51:46.690575",
    "risk_assessment": {
      "risk_label": "Safe",
      "confidence_score": 0.95,
      "severity": "none"
    },
    "cpic_guidelines": {
      "recommendation_level": "1A",
      "strength_of_recommendation": "Strong",
      "clinical_guidance": "Normal metabolizers: Use standard dosing protocol with frequent INR monitoring.",
      "cpic_evidence": "1A - Strong",
      "reference": "CPIC Warfarin/CYP2C9/VKORC1 Guidelines"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "CYP2D6",
      "diplotype": "*1/*2",
      "phenotype": "IM",
      "detected_variants": [
        {
          "rsid": "rs3288976",
          "gene": "CYP2D6",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "CYP2C19",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "CYP2C9",
          "genotype": "*1/*2",
          "phenotype": "Normal Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "TPMT",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs7364978",
          "gene": "SLC01B1",
          "genotype": "*2/*2",
          "phenotype": "Unknown"
        },
        {
          "rsid": "rs3288976",
          "gene": "DPYD",
          "genotype": "*1/*2",
          "phenotype": "Normal Metabolizer"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Use standard initiation: 5-10 mg daily; adjust based on INR response",
      "dosing": "100% - Standard dosing% adjustment",
      "monitoring": "INR monitoring: baseline, 2-7 days after initiation, weekly x 1-2 weeks, then every 1-4 weeks"
    },
    "llm_generated_explanation": {
      "summary": "Based on genetic profile, Warfarin shows safe risk.",
      "clinical_impact": "CYP2C9 (Normal Metabolizer): Safe | VKORC1: No variant data available"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": [
        "CYP2D6",
        "CYP2C19",
        "CYP2C9",
        "TPMT",
        "SLC01B1",
        "DPYD"
      ],
      "variant_count": 6,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v2"
    }
  },
  {
    "patient_id": "PATIENT_32EFBAC6",
    "drug": "Clopidogrel",
    "timestamp": "2026-02-19T16:51:46.690575",
    "risk_assessment": {
      "risk_label": "Adjust Dosage",
      "confidence_score": 0.95,
      "severity": "moderate"
    },
    "cpic_guidelines": {
      "recommendation_level": "2B",
      "strength_of_recommendation": "Moderate",
      "clinical_guidance": "Intermediate metabolizers have reduced antiplatelet effect; may not achieve therapeutic levels.",
      "cpic_evidence": "2B - Moderate",
      "reference": "CPIC Clopidogrel/CYP2C19 Guidelines"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "CYP2D6",
      "diplotype": "*1/*2",
      "phenotype": "IM",
      "detected_variants": [
        {
          "rsid": "rs3288976",
          "gene": "CYP2D6",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "CYP2C19",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "CYP2C9",
          "genotype": "*1/*2",
          "phenotype": "Normal Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "TPMT",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs7364978",
          "gene": "SLC01B1",
          "genotype": "*2/*2",
          "phenotype": "Unknown"
        },
        {
          "rsid": "rs3288976",
          "gene": "DPYD",
          "genotype": "*1/*2",
          "phenotype": "Normal Metabolizer"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Consider alternative P2Y12 inhibitor (prasugrel 5-10 mg daily or ticagrelor 60-90 mg daily) OR increase clopidogrel to 150 mg daily",
      "dosing": "200% increase (150 mg) if continuing clopidogrel% adjustment",
      "monitoring": "Assess antiplatelet response; platelet function testing helpful; higher stent thrombosis risk"
    },
    "llm_generated_explanation": {
      "summary": "Based on genetic profile, Clopidogrel shows adjust dosage risk.",
      "clinical_impact": "CYP2C19 (Intermediate Metabolizer): Adjust Dosage"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": [
        "CYP2D6",
        "CYP2C19",
        "CYP2C9",
        "TPMT",
        "SLC01B1",
        "DPYD"
      ],
      "variant_count": 6,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v2"
    }
  },
  {
    "patient_id": "PATIENT_32EFBAC6",
    "drug": "Azathioprine",
    "timestamp": "2026-02-19T16:51:46.690575",
    "risk_assessment": {
      "risk_label": "Adjust Dosage",
      "confidence_score": 0.95,
      "severity": "moderate"
    },
    "cpic_guidelines": {
      "recommendation_level": "1A",
      "strength_of_recommendation": "Strong",
      "clinical_guidance": "Intermediate activity: Increased accumulation of toxic 6-TGN metabolites.",
      "cpic_evidence": "1A - Strong",
      "reference": "CPIC Azathioprine/TPMT Guidelines"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "CYP2D6",
      "diplotype": "*1/*2",
      "phenotype": "IM",
      "detected_variants": [
        {
          "rsid": "rs3288976",
          "gene": "CYP2D6",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "CYP2C19",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "CYP2C9",
          "genotype": "*1/*2",
          "phenotype": "Normal Metabolizer"
        },
        {
          "rsid": "rs3288976",
          "gene": "TPMT",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer"
        },
        {
          "rsid": "rs7364978",
          "gene": "SLC01B1",
          "genotype": "*2/*2",
          "phenotype": "Unknown"
        },
        {
          "rsid": "rs3288976",
          "gene": "DPYD",
          "genotype": "*1/*2",
          "phenotype": "Normal Metabolizer"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Reduce dose 25-50% of normal; start low and titrate carefully based on response",
      "dosing": "50% reduction recommended% adjustment",
      "monitoring": "CBC weekly x 4-6 weeks, then every 2 weeks. Watch closely for infections, severe anemia, platelet drops"
    },
    "llm_generated_explanation": {
      "summary": "Based on genetic profile, Azathioprine shows adjust dosage risk.",
      "clinical_impact": "TPMT (Intermediate Metabolizer): Adjust Dosage"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": [
        "CYP2D6",
        "CYP2C19",
        "CYP2C9",
        "TPMT",
        "SLC01B1",
        "DPYD"
      ],
      "variant_count": 6,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v2"
    }
  }
]